Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neolixir Limited maintains a focused presence in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action, indicating a specific and limited scope of active patent prosecution. This 1 pending office action is the primary focus of the company's current interactions with the patent office.
The prosecution is centralized, with 1 distinct examiner and 1 distinct art unit assigned to the pending work. This suggests that the company's intellectual property is concentrated in a specific scientific niche within the broader Biotechnology & Pharmaceuticals field. NESTOR, DONNA MICHELLE is the busiest examiner for the portfolio, handling 1 busiest examiner pending office action. Consequently, the progress of the company's entire pending pipeline is currently determined by the review of this 1 distinct examiner.
Strategic management of this portfolio is simplified by the involvement of only 1 distinct art unit, allowing for a tailored approach to that unit's specific practices. The 1 busiest examiner pending office action under NESTOR, DONNA MICHELLE represents the total active workload, meaning that the outcome of this case will define the company's immediate success. Practitioners can focus their efforts on understanding the specific requirements associated with this 1 distinct examiner and 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693998 | METHODS FOR BIOFILM DISRUPTION | NESTOR, DONNA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693998 | METHODS FOR BIOFILM DISRUPTION | NESTOR, DONNA MICHELLE | 1627 | §102DP | Non-Final OA | — | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial